|drug2035||MethylPREDNISolone 80 Mg/mL Injectable Suspension Wiki||1.00|
|D012127||Respiratory Distress Syndrome, Newborn NIH||0.09|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.08|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
There is one clinical trial.
The study aims to evaluate the reduction in severity and progression of lung injury with three doses of lipid ibuprofen in patients with SARS-CoV-2 infections.
Description: Worsening respiratory failure; defined using severity of hypoxaemia using [PaO2/FiO2 ratio OR SpO2/FiO2 ratio]Measure: Disease progression Time: 14 days
Description: Time to mechanical ventilation (or need of)Measure: Time to mechanical ventilation Time: 14 days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports